4:56 PM
 | 
Apr 04, 2019
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Jounce reports detailed data backing tumor-agnostic approach

Jounce reported detailed PFS and OS data at AACR for vopratelimab (JTX-2011) that support a tumor-agnostic approach for the ICOS agonist to select patient populations more likely to respond to the therapy.

At the American Association for Cancer Research meeting in Atlanta, Jounce Therapeutics Inc. (NASDAQ:JNCE) reported detailed data from the adaptive Phase I/II ICONIC trial to treat advanced solid tumors showing...

Read the full 288 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >